For patients with advanced emphysema, EBV is associated with higher mortality and morbidity compared with LVRS.

according to a notice from the Roy Castle Lung Cancer Foundation. Previously, EGFR mutation-positive NSCLC patients relied on chemotherapy to prevent cancer recurrence after surgery, according to ...

Revenues increased 34% compared to the previous quarter ended September 30, 2024; and exceeded $1 millionReceived CE Mark for LungFit PH® in ...

Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...

The risk of developing liver cancer is increased in people who have cirrhosis, a disease in which healthy liver tissue is ...

Inc. (NASDAQ: BNAI) reported its third-quarter fiscal year 2025 earnings, revealing a significant revenue increase and a narrowing net loss. The company's earnings per share (EPS) matched expectations ...